<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6789886\results\search\tropicalVirus\results.xml">
  <result pre="italic;} Vaccines (Basel)Vaccines (Basel)vaccinesVaccines2076-393XMDPI pmcid: 6789886 doi: 10.3390/vaccines7030072vaccines-07-00072 : Article" exact="Zika" post="Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces"/>
  <result pre="Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of" exact="Dengue" post="Virus Infection Cabral-MirandaGustavo12*LimStephanie M.3https://orcid.org/0000-0003-3510-9148MohsenMona O.12PobelovIlya V.4RoestiElisa S.2HeathMatthew D.5SkinnerMurray A.5https://orcid.org/0000-0002-3740-4733KramerMatthias"/>
  <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus (ZIKV) is a flavivirus similar to Dengue virus"/>
  <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Zika virus (ZIKV) is a flavivirus similar to" exact="Dengue" post="virus (DENV) in terms of transmission and clinical manifestations,"/>
  <result pre="clinical manifestations, and usually both viruses are found to co-circulate." exact="ZIKV" post="is usually transmitted by mosquitoes bites, but may also"/>
  <result pre="and sexually. After 2015, when the most extensive outbreak of" exact="ZIKV" post="had occurred in Brazil and subsequently spread throughout the"/>
  <result pre="throughout the rest of South America, it became evident that" exact="ZIKV" post="infection during the first trimester of pregnancy was associated"/>
  <result pre="newborns. As a result, the development of a vaccine against" exact="ZIKV" post="became an urgent goal. A major issue with DENV"/>
  <result pre="against ZIKV became an urgent goal. A major issue with" exact="DENV" post="vaccines, and therefore likely also with ZIKV vaccines, is"/>
  <result pre="major issue with DENV vaccines, and therefore likely also with" exact="ZIKV" post="vaccines, is the induction of antibodies that fail to"/>
  <result pre="for ADE for other viral strains. Therefore, we generated a" exact="ZIKV" post="vaccine based on the EDIII domain displayed on the"/>
  <result pre="after a single injection. The antibodies were able to neutralise" exact="ZIKV" post="without enhancing infection by DENV in vitro. Thus, the"/>
  <result pre="antibodies were able to neutralise ZIKV without enhancing infection by" exact="DENV" post="in vitro. Thus, the here described vaccine based on"/>
  <result pre="VLPs was able to stimulate production of antibodies specifically neutralizing" exact="ZIKV" post="without potentially enhancing disease caused by DENV. vaccine Zika"/>
  <result pre="neutralizing ZIKV without potentially enhancing disease caused by DENV. vaccine" exact="Zika" post="virus envelop (E) protein domain III (EDIII) virus like"/>
  <result pre="(EDIII) virus like particles (VLPs) dioleoyl phosphatidylserine (DOPS) 1. Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus transmitted to humans"/>
  <result pre="Aedes mosquitoes [1,2]. In recent years, it was found that" exact="ZIKV" post="may also be transmitted among humans without participation of"/>
  <result pre="for example by blood transfusion, maternal–foetal transmission, and sexually [3,4,5,6]." exact="ZIKV" post="is not a new virus and was first identified"/>
  <result pre="new virus and was first identified in 1947 in the" exact="Zika" post="Forest of Uganda, Africa [1,7], with the first human"/>
  <result pre="in the 1950s. Before the outbreak in Brazil in 2015," exact="ZIKV" post="was not well known worldwide. Only thereafter, and when"/>
  <result pre="ZIKV was not well known worldwide. Only thereafter, and when" exact="ZIKV" post="infection became associated with microcephaly and cases of Guillain-Barré"/>
  <result pre="associated with microcephaly and cases of Guillain-Barré syndrome [8,9,10,11], did" exact="ZIKV" post="call attention of the public as well as health"/>
  <result pre="health authorities worldwide, and the World Health Organization (WHO) declared" exact="ZIKV" post="as a Public Health Emergency of International Concern in"/>
  <result pre="a Public Health Emergency of International Concern in 2016 [12]." exact="ZIKV" post="shares considerable genetic and structural similarity with other flaviviruses,"/>
  <result pre="considerable genetic and structural similarity with other flaviviruses, for example," exact="Dengue" post="virus (DENV) [13], which is also transmitted by Aedes"/>
  <result pre="it is well established that previous infection with a different" exact="DENV" post="serotype may predispose to a more serious disease such"/>
  <result pre="Most preclinical and clinical programs aimed to develop vaccines against" exact="ZIKV" post="have focused on attenuated or inactivated viruses as well"/>
  <result pre="contrast, the E-DIII domain may be the best target for" exact="ZIKV" post="vaccine development, as antibodies recognising this domain are largely"/>
  <result pre="models [36]. In this study, we developed a vaccine-candidate against" exact="ZIKV" post="by coupling E-DIII to CuMVttVLP and formulating the product"/>
  <result pre="efficiently and neutralise the virus without predisposing for ADE with" exact="DENV" post="infections. ZIKV and DENV are flaviviruses that circulate mostly"/>
  <result pre="neutralise the virus without predisposing for ADE with DENV infections." exact="ZIKV" post="and DENV are flaviviruses that circulate mostly in the"/>
  <result pre="virus without predisposing for ADE with DENV infections. ZIKV and" exact="DENV" post="are flaviviruses that circulate mostly in the same environmental"/>
  <result pre="new vaccine candidate warrants further development. 2. Experimental Section 2.1." exact="Zika" post="Virus (ZIKV) E-DIII Protein Production The cloning and production"/>
  <result pre="Virus (ZIKV) E-DIII Protein Production The cloning and production of" exact="ZIKV" post="envelope protein domain III was published recently [37]. Briefly"/>
  <result pre="III was published recently [37]. Briefly the E-DIII gene of" exact="Zika" post="virus Brazil-ZKV2015 strain was selected from GenBank, reference number"/>
  <result pre="8.0 and subsequently purified on a Ni Sepharose resin. The" exact="ZIKV" post="ED-III protein, after purification, was refolded by dialysis. First"/>
  <result pre="were subtracted from the titres of the vaccinated groups. 2.6." exact="Zika" post="Virus Neutralization Assay The test of neutralizing capacity of"/>
  <result pre="tested in two independent experiments. 2.7. Antibody-Dependent Enhancement Test with" exact="Dengue" post="Virus (DENV-2) The ADE test was performed using THP-1"/>
  <result pre="3. Results 3.1. Choosing the Target Epitope to Design a" exact="ZIKV" post="Vaccine The development of vaccines against flaviviruses represents a"/>
  <result pre="maximize neutralization and minimize cross-reactivity. It has been shown for" exact="DENV" post="that domain III of the envelope proteins (EDIII) is"/>
  <result pre="[37]. Furthermore, we have previously shown that the EDIII-domain of" exact="West Nile" post="virus (WNV), another flavivirus, induced highly neutralizing and protective"/>
  <result pre="displayed on VLPs [42]. We therefore expressed the EDIII of" exact="ZIKV" post="with a small linker containing a free Cys for"/>
  <result pre="we have performed a CPE-based neutralization assay using a representative" exact="ZIKV" post="strain inducing good CPE (Figure 4). As shown in"/>
  <result pre="vaccinated with VLP-EDIII+DOPS developed antibody responses able to neutralise the" exact="ZIKV" post="after two vaccinations (Day 42). In contrast, mice vaccinated"/>
  <result pre="to induce measurable levels of neutralizing antibodies. 3.4. Assessment of" exact="ZIKV" post="Antibody-Dependent Enhancement with DENV-2 Enhanced infection due to cross-reactive"/>
  <result pre="for DENV. DENV-2 is considered to be the most virulent" exact="DENV" post="serotype with a genetically diverse population and is most"/>
  <result pre="antibodies may cross-react with DENV, a key feature of a" exact="ZIKV" post="vaccine candidate is that it must not induce antibodies"/>
  <result pre="candidate is that it must not induce antibodies that enhance" exact="DENV" post="infection. As described in the schematic figure (Figure 6a,b)"/>
  <result pre="destroy the virus. However, as shown in Figure 6b, when" exact="ZIKV" post="is recognised by non-neutralizing antibodies, the antibody binding will"/>
  <result pre="As seen in Figure 6c,d, the qRT-PCR results demonstrate that" exact="ZIKV" post="specific serum antibodies induced by vaccination did not promote"/>
  <result pre="induced by vaccination did not promote the synthesis of more" exact="DENV" post="RNA as measured in the supernatants. Under none of"/>
  <result pre="not inducing ADE antibodies. 4. Discussion The widespread outbreak of" exact="ZIKV" post="in the Americas and its causal association with severe"/>
  <result pre="non-enhancing antibodies. Several studies have shown that immune responses to" exact="ZIKV" post="were similar to responses induced against other flaviviruses such"/>
  <result pre="were similar to responses induced against other flaviviruses such as" exact="DENV" post="or WNV. Specifically, it has been shown that neutralising"/>
  <result pre="antibodies may result in enhancement of infection or disease with" exact="ZIKV" post="or DENV [18,47]. Therefore, the issue of enhancement has"/>
  <result pre="result in enhancement of infection or disease with ZIKV or" exact="DENV" post="[18,47]. Therefore, the issue of enhancement has to be"/>
  <result pre="to be considered when developing vaccines against flavivirus, such as" exact="ZIKV" post="and DENV [14,15,16,17,18,19,20,21]. In this study we have shown"/>
  <result pre="considered when developing vaccines against flavivirus, such as ZIKV and" exact="DENV" post="[14,15,16,17,18,19,20,21]. In this study we have shown that a"/>
  <result pre="study we have shown that a VLPs vaccine candidate carrying" exact="ZIKV" post="E-DIII induced neutralizing antibodies, but no enhancement against DENV-2"/>
  <result pre="against DENV-2 was observed. The number of vaccine candidates against" exact="ZIKV" post="have increased recently and some of them have advanced"/>
  <result pre="non-neutralizing and cross-reactive antibodies that could enhance disease of either" exact="ZIKV" post="or DENV. Vaccines based on E-DIII are likely to"/>
  <result pre="and enhancing antibodies. Indeed, a recent publication has demonstrated that" exact="Zika" post="EDIII-domain fused to hepatitis B core Antigen (HBcAg) induces"/>
  <result pre="Antigen (HBcAg) induces potent neutralizing antibodies in mice without enhancing" exact="DENV" post="virus infection in vitro [49]. Immunogenicity of the candidate"/>
  <result pre="DENV virus infection in vitro [49]. Immunogenicity of the candidate" exact="ZIKV" post="vaccine was tested in Balb/C mice. We wanted to"/>
  <result pre="neutralizing titers. We have shown that complement alone can inactivate" exact="ZIKV" post="and DENV (unpublished) and, therefore, we did not study"/>
  <result pre="We have shown that complement alone can inactivate ZIKV and" exact="DENV" post="(unpublished) and, therefore, we did not study complement-dependent neutralization"/>
  <result pre="with other serotypes or genotypes could be enhanced by the" exact="ZIKV" post="antibodies. Therefore, studies investigating enhancement activity of flavivirus cross-reactive"/>
  <result pre="analysis and wrote the paper; S.M.L. and B.E.E.M.: performed the" exact="ZIKV" post="neutralization assay and cross-reactivity and ADE test with DENV;"/>
  <result pre="Aegypti and Aedes AlbopictusECDCStockholm, Sweden2016 3.TurmelJ.M.AbgueguenP.HubertB.VandammeY.M.MaquartM.Le Guillou-GuillemetteH.Leparc-GoffartI.Late sexual transmission of" exact="Zika" post="virus related to persistence in the semenLancet2016387250110.1016/S0140-6736(16)30775-927287833 4.MansuyJ.M.PasquierC.DaudinM.Chapuy-RegaudS.MoinardN.ChevreauC.IzopetJ.MengelleC.BujanL.Zika virus"/>
  <result pre="a patient returning from a non-epidemic areaLancet Infect. Dis.20161689489510.1016/S1473-3099(16)30153-0 5.FiorentinoD.G.MonteroF.J.The" exact="Zika" post="Virus and PregnancyCurr. Obstet. Gynecol. Rep.2016523423810.1007/s13669-016-0171-1 6.MussoD.StramerS.L.BuschM.P.Zika virus: A"/>
  <result pre="syndrome in Colombia: Epidemiological situation during 21 months of the" exact="Zika" post="virus outbreak, 2015–2017Arch. Public Health2017756510.1186/s13690-017-0233-529118981 10.BarbiL.CoelhoA.V.C.AlencarL.C.A.CrovellaS.Prevalence of Guillain-Barré syndrome"/>
  <result pre="virus outbreak, 2015–2017Arch. Public Health2017756510.1186/s13690-017-0233-529118981 10.BarbiL.CoelhoA.V.C.AlencarL.C.A.CrovellaS.Prevalence of Guillain-Barré syndrome among" exact="Zika" post="virus infected cases: A systematic review and meta-analysisBraz. J."/>
  <result pre="Infect. Dis.20182213714110.1016/j.bjid.2018.02.00529545017 11.StyczynskiA.R.MaltaJ.M.A.S.Krow-LucalE.R.PercioJ.NobregaM.E.VargasA.LanzieriT.M.LeiteP.L.StaplesJ.E.FischerM.X.et al.Increased rates of Guillain-Barre’ syndrome associated with" exact="Zika" post="virus outbreak in the Salvador metropolitan area, BrazilPLoS Negl."/>
  <result pre="the International Health Regulations (2005) (IHR 2005) Emergency Committee on" exact="Zika" post="Virus and Observed Increase in Neurological Disorders and Neonatal"/>
  <result pre="on 4 March 2019) 13.HuberRG.LimX.N.NgW.C.SimA.Y.L.PohH.X.ShenY.LimS.Y.SundstromK.B.SunX.AwJ.G.et al.Structure mapping of dengue and" exact="Zika" post="viruses reveals functional long-range interactionsNat. Commun.201910140810.1038/s41467-019-09391-830926818 14.DejnirattisaiW.SupasaP.WongwiwatW.RouvinskiA.Barba-SpaethG.DuangchindaT.Dengue virus sero-cross-reactivity"/>
  <result pre="antibody responses after dengue virus infection are highly cross-reactive to" exact="Zika" post="virusProc. Natl. Acad. Sci. USA20161137852785710.1073/pnas.160793111327354515 16.KawieckiA.B.ChristoffersonR.C.Zika Virus-Induced Antibody Response"/>
  <result pre="virusProc. Natl. Acad. Sci. USA20161137852785710.1073/pnas.160793111327354515 16.KawieckiA.B.ChristoffersonR.C.Zika Virus-Induced Antibody Response Enhances" exact="Dengue" post="Virus Serotype 2 Replication In VitroJ. Infect. Dis.20162141357136010.1093/infdis/jiw37727521359 17.Martín-AcebesM.A.Juan-CarlosS.de"/>
  <result pre="humansScience201032874574810.1126/science.118518120448183 19.StettlerK.BeltramelloM.EspinosaD.A.GrahamV.CassottaA.BianchiS.VanzettaF.MinolaA.JaconiS.MeleF.et al.Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infectionScience201635382382610.1126/science.aaf850527417494 20.CastanhaP.M.S.NascimentoE.J.M.BragaC.CordeiroM.T.CarvalhoO.V.MendonçaL.R.Dengue virus (DENV)-specific antibodies enhance Brazilian Zika"/>
  <result pre="by Zika virus infectionScience201635382382610.1126/science.aaf850527417494 20.CastanhaP.M.S.NascimentoE.J.M.BragaC.CordeiroM.T.CarvalhoO.V.MendonçaL.R.Dengue virus (DENV)-specific antibodies enhance Brazilian" exact="Zika" post="virus (ZIKV) infectionJ. Infect. Dis.201721578178510.1093/infdis/jiw63828039355 21.KhandiaR.MunjalA.DhamaK.KarthikK.TiwariR.MalikY.S.SinghR.K.ChaicumpaW.Modulation of Dengue/Zika Virus"/>
  <result pre="by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in" exact="Zika" post="Virus InfectionFront. Immunol.2018959710.3389/fimmu.2018.0059729740424 22.BarrettA.D.T.Current status of Zika vaccine development:"/>
  <result pre="Against Enhancement in Zika Virus InfectionFront. Immunol.2018959710.3389/fimmu.2018.0059729740424 22.BarrettA.D.T.Current status of" exact="Zika" post="vaccine development: Zika vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012"/>
  <result pre="Zika Virus InfectionFront. Immunol.2018959710.3389/fimmu.2018.0059729740424 22.BarrettA.D.T.Current status of Zika vaccine development:" exact="Zika" post="vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012 23.MakhlufH.ShrestaS.Development of Zika"/>
  <result pre="development: Zika vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012 23.MakhlufH.ShrestaS.Development of" exact="Zika" post="Virus VaccinesVaccines20186710.3390/vaccines6010007 24.RichnerJ.M.DiamondM.S.Zika virus vaccines: Immune response, current status,"/>
  <result pre="Opin. Immunol.20185313013610.1016/j.coi.2018.04.02429753210 25.WahidB.AliA.RafiqueS.IdreesM.Current status of therapeutic and vaccine approaches against" exact="Zika" post="virusEur J. Intern. Med.201744121810.1016/j.ejim.2017.08.00128797534 26.Barba-SpaethG.DejnirattisaiW.RouvinskiA.VaneyM.C.MeditsI.SharmaA.Simon-LorièreE.SakuntabhaiA.Cao-LormeauV.M.HaouzA.et al.Structural basis of potent"/>
  <result pre="against Malaria for VLP-TRAP Based VaccinesDiseases2018610710.3390/diseases604010730469323 37.Cabral-MirandaG.CardosoA.R.FerreiraL.C.S.SalesM.G.F.BachmannM.F.Biosensor-based selective detection of" exact="Zika" post="virus specific antibodies in infected individualsBiosens. Bioelectron.201811310110710.1016/j.bios.2018.04.05829751200 38.Cabral-MirandaG.HeathM.D.MohsenM.O.GomesA.C.EngeroffP.FlaxmanA.LeorattiF.M.S.El-TurabiA.Reyes-SandovalA.SkinnerM.A.et al.Virus-Like"/>
  <result pre="Cell Immunogenicity and Protection against Plasmodium berghei/vivaxVaccines201751010.3390/vaccines502001028468322 39.BarzonL.PacentiM.BertoA.SinigagliaA.FranchinE.LavezzoE.BrugnaroP.PalùG.Isolation of infectious" exact="Zika" post="virus from saliva and prolonged viral RNA shedding in"/>
  <result pre="Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus," exact="Dengue" post="Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCRJ."/>
  <result pre="Clin. Microbiol.2002402323233010.1128/JCM.40.7.2323-2330.200212089242 42.SpohnG.JenningsG.T.MartinaB.E.KellerI.BeckM.PumpensP.OsterhausA.D.BachmannM.F.A VLP-based vaccine targeting domain III of the" exact="West Nile" post="virus E protein protects from lethal infection in miceVirol."/>
  <result pre="45.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 46.ZhaoH.FernandezE.DowdK.A.SpeerS.D.PlattD.J.GormanM.J.GoveroJ.NelsonC.A.PiersonT.C.DiamondM.S.et al.Structural Basis of"/>
  <result pre="Zika virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 46.ZhaoH.FernandezE.DowdK.A.SpeerS.D.PlattD.J.GormanM.J.GoveroJ.NelsonC.A.PiersonT.C.DiamondM.S.et al.Structural Basis of" exact="Zika" post="Virus-Specific Antibody ProtectionCell20161661016102710.1016/j.cell.2016.07.02027475895 47.ZimmermanM.G.QuickeK.M.O’NealJ.T.AroraN.MachiahD.PriyamvadaL.KauffmanR.C.RegisterE.AdekunleO.SwiebodaD.et al.Cross-Reactive Dengue Virus Antibodies Augment"/>
  <result pre="46.ZhaoH.FernandezE.DowdK.A.SpeerS.D.PlattD.J.GormanM.J.GoveroJ.NelsonC.A.PiersonT.C.DiamondM.S.et al.Structural Basis of Zika Virus-Specific Antibody ProtectionCell20161661016102710.1016/j.cell.2016.07.02027475895 47.ZimmermanM.G.QuickeK.M.O’NealJ.T.AroraN.MachiahD.PriyamvadaL.KauffmanR.C.RegisterE.AdekunleO.SwiebodaD.et al.Cross-Reactive" exact="Dengue" post="Virus Antibodies Augment Zika Virus Infection of Human Placental"/>
  <result pre="Zika Virus-Specific Antibody ProtectionCell20161661016102710.1016/j.cell.2016.07.02027475895 47.ZimmermanM.G.QuickeK.M.O’NealJ.T.AroraN.MachiahD.PriyamvadaL.KauffmanR.C.RegisterE.AdekunleO.SwiebodaD.et al.Cross-Reactive Dengue Virus Antibodies Augment" exact="Zika" post="Virus Infection of Human Placental MacrophagesCell Host Microbe20182473174210.1016/j.chom.2018.10.00830439342 48.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development"/>
  <result pre="of Human Placental MacrophagesCell Host Microbe20182473174210.1016/j.chom.2018.10.00830439342 48.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against" exact="Zika" post="virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 49.YangM.LaiH.SunH.ChenQ.Virus-like particles that display Zika virus"/>
  <result pre="vaccines against Zika virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 49.YangM.LaiH.SunH.ChenQ.Virus-like particles that display" exact="Zika" post="virus envelope protein domain III induce potent neutralizing immune"/>
  <result pre="observational studyPLoS Negl. Trop. Dis.201812e000681710.1371/journal.pntd.000681730226880 55.GallichotteE.N.BaricT.J.NivarthiU.DelacruzM.J.GrahamR.WidmanD.G.YountB.L.DurbinA.P.WhiteheadS.S.de SilvaA.M.et al.Genetic Variation between" exact="Dengue" post="Virus Type 4 Strains Impacts Human Antibody Binding and"/>
  <result pre="and atomic force microscopy (AFM) images. (a) The conjugation of" exact="Zika" post="virus E-DIII protein was done by modifying the CuMVttVLP"/>
  <result pre="of a ZIKV-specific antibodies to prevent cpe. Cells infected with" exact="ZIKV" post="pre-incubated with sera from immunized mice showed no CPA"/>
  <result pre="+ virus). Cytopathic effect (CPE) was seen in serum without" exact="ZIKV" post="specific antibodies (Negative serum + Virus), comparable to cultures"/>
  <result pre="(Negative serum + Virus), comparable to cultures infected only with" exact="ZIKV" post="(Virus control). The panel &quot;Cell control�? shows uninfected cells."/>
  <result pre="control). The panel &quot;Cell control�? shows uninfected cells. Figure 5" exact="ZIKV" post="neutralising capacity assessment. The figure shows the titer of"/>
  <result pre="has been completely opsonised by neutralizing antibody (a) and when" exact="ZIKV" post="is recognised by non-neutralizing antibodies, the antibody binding will"/>
 </snippets>
</snippetsTree>
